The role of microRNAs in the pathogenesis and progression of liver diseases
Abstract
Keywords
Full Text:
PDF (Język Polski)References
Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: Function, detection, and bioanalysis. Chem Rev 2013;113(8):6207-33.
Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80(2):193-208.
Hepatitis B. Fact sheet 204. World Healt Organization; 2016. http://www. who.int/mediacentre/factsheets/fs204/en/ (13.04.2016).
Sarkar N, Chakravarty R. Hepatitis B. Virus infection, microRNAs and liver disease. Int J Mol Sci 2015;16(8):17746-62.
Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al.Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997;94(26):14707-12.
Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011;3(1):44-50. doi: 10.1093/jmcb/mjq040.
Lim KH, Choi HS, Park YK, Park ES, Shin GC, Kim DH, et al. HBx-induced NF-κB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS One 2013;8(3):e57331.
Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. MBio 2015;6(2):e02459-14.
Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol 2012;56(4):855-61.
Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer 2011;105(1):146-53.
Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011;6(5):e19518.
Ren M, Qin D, Li K, Qu J, Wang L, Wang Z, et al. Correlation between hepatitis B virus protein and microRNA processor Drosha in cells expressing HBV. Antiviral Res 2012;94(3)225-31.
Bandopadhyay M, Banerjee A, Sarkar N, Panigrahi R, Datta S, Pal A, et al. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC Cancer 2014;14:721.
Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, et al. Lethal-7 is downregulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010;53(1):57-66. doi: 10.1016/j.jhep.2009.12.043.
Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, et al. MiR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013;25(2):439-46. doi: 10.1016/j.cellsig.2012.10.013.
Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 2013;25(5):1037-43.
Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, et al. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia 2013;15(11):1282-91.
Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011;53(5):1476-85.
Dai X, Zhang W, Zhang H, Sun S, Yu H, Guo Y, et al. Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1α. Nucleic Acids Res 2014;42(10):6578-90.
Guo H, Liu H, Mitchelson K, Rao H, Luo M, Xie L, et al. MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology 2011;54(3):808-19.
Jin J, Tang S, Xia L, Du R, Xie H, Song J, et al. MicroRNA-501 promotes HBV replication by targeting HBXIP. Biochem Biophys Res Commun 2013;430(4):1228-33.
Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010;88(2):169-75.
Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 2011;39(12):5157-63.
Huang JY, Chou SF, Lee JW, Chen HL, Chen CM, Tao MH, et al. MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ. RNA 2015;21(3):385-400.
Hu W, Wang X, Ding X, Li Y, Zhang X, Xie P, et al. MicroRNA-141 represses HBV replication by targeting PPARA. PLoS One 2012;7(3):e34165.
Wu FL, Jin WB, Li JH, Guo AG. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011;42(2):157-61.
Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012;55(3):730-41.
Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. MiR-122-induced downregulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010;398(4):771-7.
Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009;49(5):1571-82.
Hepatitis C. Fact sheet 164. World Healt Organization; 2016. http://www. who.int/mediacentre/factsheets/fs164/en/ (13.04.2016).
Conrad KD, Niepmann M. The role of microRNAs in hepatitis C virus RNA replication. Arch Virol 2014;159(5):849-62.
Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 2013;110(5):1881-6. doi: 10.1073/pnas.1213515110.
Machlin ES, Sarnow P, Sagan SM. Masking the 5’ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011;108(8):3193-8.
Motavaf M, Safari S, Alavian SM. Targeting microRNA-122: walking on cutting edge of hepatitis C virus infection therapy. Acta Virol 2014;58(4): 301-8.
Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012;69(15):2621-33.
Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009;50(3):453-60.
Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007;449(7164):919-22.
Mukherjee A, Shrivastava S, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol 2014;88(14):7929-40.
Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, et al. Review article: alcoholic liver disease: pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006;24(8):1151-61.
Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Upregulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011;286(2):1436-44.
Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008;32(2):355-64.
Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012;287(13):9817-26.
Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009;33(10):1704-10.
Yeligar S, Tsukamoto H, Kalra VK. Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol 2009;183(8):5232-43.
Kang T, Lu W, Xu W, Anderson L, Bacanamwo M, Thompson W, et al. MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells. J Biol Chem 2013;288(48):34394-402. doi: 10.1074/jbc.M113.514372.
Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, et al. MiR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep 2015;33(2):713-20.
Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013;57(1):70-80.
Hou W, Bukong TN, Kodys K, Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013;37(4):599-608.
Habior A. Nonalcoholic fatty liver disease and obesity. Post Nauk Med 2013;5b:31-7.
Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010;90(10): 1437-46.
Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008;48(6):1810-20. doi: 10.1002/hep.22569.
Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011;91(2):283-93.
Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69(15):6275-81.
Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006;103(33):12481- 6. doi: 10.1073/pnas.0605298103.
Tang B, Xiao B, Liu Z, Li N, Zhu ED, Li BS, et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett 2010;584(8):1481-6. doi: 10.1016/j.febslet.2010.02.063.
Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines theepithelial phenotype of cancer cells by targeting the E-cadherin repressors
Ahn J, Lee H, Chung CH, Ha T. High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochem Biophys Res Commun 2011;414(4):664-9
Zhang Y, Cheng X, Lu Z, Wang J, Chen H, Fan W, et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver diseaseDiabetes Res Clin Pract 2013;99(3):327-34..
Zhang ZC, Liu Y, Xiao LL, Li SF, Jiang JH, Zhao Y, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol 2015;63(6):1466-75.
Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med 2015;139(7):876-87.
Fukushima T, Hamada Y, Yamada H, Horii I. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride – regulating role of micro-RNA for RNA expression. J Toxicol Sci 2007;32(4):401-9.
Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 2007;619(1-2):30-7.
Endo S, Yano A, Fukami T, Nakajima M, Yokoi T. Involvement of miRNAs in the early phase of halothane-induced liver injury. Toxicology 2014;319:75-84.
Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106(11):4402-7.
Yoshioka W, Higashiyama W, Tohyama C. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol Sci 2011;122(2):457-65.
Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009;315(8):1439-47.
Moffat ID, Boutros PC, Celius T, Lindén J, Pohjanvirta R, Okey AB. MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci 2007;99(2):470-87.
Yang W, Lian J, Feng Y, Srinivas S, Guo Z, Zhong H, et al. Genome-wide miRNA-profiling of aflatoxin B1-induced hepatic injury using deep sequencing. Toxicol Lett 2014;226(2):140-9.
Malik AI, Williams A, Lemieux CL, White PA, Yauk CL. Hepatic mRNA, microRNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. Environ Mol Mutagen 2012;53(1):10-21.
Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32(3-4):246-53.
Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Upregulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56(2):687-97.
Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D, et al. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One 2014;9(10):e111424.
Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One 2015;(11):e0136908.
Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One 2015;10(10):e0139305.
Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol 2016;185(1):61-71. doi: 10.1111/cei.12776.
Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, et al. MiR-183 inhibits TGF-beta1- induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 2010;10:354.
Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 2010;53(1):98-107.
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. MiR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275(1):44-53.
Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012;33(6):1134-41.
Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, et al. Hepatitis C virusinduced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012;56(5)1631-40. doi: 10.1002/hep.25849.
Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010;16(3):867-75.
Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep 2012;5(6):1428-32. doi: 10.3892/mmr.2012.838.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39):13944-9.
Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY, et al. Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. Int J Cancer 2014;134(7):1638-47.
Yan X, Liang H, Deng T, Zhu K, Zhang S, Wang N, et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer 2013;12:92.
Asangani I, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27(15):2128-36.
Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282(19):14328-36.
Connolly EC, van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res 2010;8(5):691-700.
Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E, et al. MiR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’UTR microRNA recognition elements. Mol Cell 2009;35(5):610-25.
Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. MiR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010;5(2):e9429.
Wang T, Xu Z. MiR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem Biophys Res Commun 2010;402(2):186-9.
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66(24):11590-3.
Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010;1(4):381-7.
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008;582(10):1564-8.
Ding J, Li M, Wan X, Jin X, Chen S, Yu C, et al. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep 2015;5:13729. doi: 10.1038/srep13729.
Niu H, Wang K, Zhang A, Yang S, Song Z, Wang W, et al. MiR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. Oncol Rep 2012;28(5):1771-7.
Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, et al. MicroRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011;286(12):10725-34.
Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, et al. Targeting DNAPKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 2010;5(7):e11397.
Wei X, Tang C, Lu X, Liu R, Zhou M, He D, et al. MiR-101 targets DUSP1 to regulate the TGF-f secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Oncotarget 2015;6(21):18389-405.
Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an antiapoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008;375(3):315-20. doi: 10.1016/j.bbrc. 2008.07.
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67(13):6092-9.
. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010;52(4):1431-42.
. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. MiR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013;58(3):522-8.
Wang HQ, Yu XD, Liu ZH, Cheng X, Samartzis D, Jia LT, et al. Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. J Pathol 2011;225(2):232-42. doi: 10.1002/path.2931.
Zhu D, Xie H, Li H, Cai P, Zhu H, Xu C, et al. Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung’s disease. J Neurochem 2015;134(1):39-46. doi: 10.1111/jnc.13118.
Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, et al. MiR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget 2016;7(3): 2672-83.
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18(4):367-81.
Zhang Y, Fan KJ, Sun Q, Chen AZ, Shen WL, Zhao ZH, et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-f signalling pathway. Nucleic Acids Res 2012;40(18):9286-97.
Shatseva T, Lee DY, Deng Z, Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci 2011;124:2826-36.
Han Y, Kuang Y, Xue X, Guo X, Li P, Wang X, et al. NLK, a novel target of miR- 199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother 2014;68(5):497-505.
Schickel R, Park SM, Murmann AE, Peter ME. MiR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010;38(6):908-15.
Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, downregulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 2012:33(1):220-5. doi: 10.1093/carcin/bgr245.
Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li XB, et al. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun 2013;4:2544. doi: 10.1038/ncomms3544.
Zhang J, Bian Z, Zhou J, Song M, Liu Z, Feng Y, et al. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein Cell 2015;6(9):680-8. doi: 10.1007/s13238-015-0187-8.
Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep 2014;8(3):714-22. doi: 10.1016/j. celrep.2014.06.064.
Xie KL, Zhang YG, Liu J, Zeng Y, Wu H. MicroRNAs associated with HBV infection and HBV-related HCC. Theranostics 2014;4(12):1176-92. doi: 10.7150/thno.8715.
Enache LS, Enache EL, Ramière C, Diaz O, Bancu L, Sin A, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci 2014;15(10):17644-66. doi: 10.3390/ijms151017644.
Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 2010;398(1):57-67.
Jiang M, Broering R, Trippler M, Wu J, Zhang E, Zhang X, et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat 2014;21(2):99-110.
Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013;5(9):479-86. doi: 10.4254/wjh.v5.i9.479.
Bala S, Szabo G. MicroRNA signature in alcoholic liver disease. Int J Hepatol 2012;2012:498232. doi: 10.1155/2012/498232.
McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P, et al. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med 2014;18(2):197-207.
Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013;33(8):1257-65.
Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56(5):1946-57.
Szabo G, Csak T. Role of microRNAs in NAFLD/NASH. Dig Dis Sci 2016;61(5):1314-24. doi: 10.1007/s10620-015-4002-4.
Sobolewski C, Calo N, Portius D, Foti M. MicroRNAs in fatty liver disease. Semin Liver Dis 2015;35(1):12-25.
Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015;7(2):226-34.
Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol 2012;262(1):52-9.
Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomark Med 2014;8(2):161-72. doi: 10.2217/bmm.13.147.
Yan S, Wang J, Zhang W, Dai J. Circulating microRNA profiles altered in mice after 28 d exposure to perfluorooctanoic acid. Toxicol Lett 2014;224(1):24-31.
Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55(11):1977-83. doi: 10.1373/ clinchem.2009.131797.
Wang J, Zhang Y, Zhang W, Jin Y, Dai J. Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. Environ Sci Technol 2012;46(17):9274-81.
Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated microRNAs in progression of hepatocellular carcinoma: A systematic review. Hepatol Res 2016;46(5):391-406. doi: 10.1111/hepr.12606.
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137(6):1005-17.
Wang C, Ren R, Hu H, Tan C, Han M, Wang X, et al. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res 2014;26(1):17-29. doi: 10.3978/j.issn.1000-9604.2014.01.01.
Chang-Hao Tsao S, Behren A, Cebon J, Christophi C. The role of circulating microRNA in hepatocellular carcinoma. Front Biosci (Landmark Ed) 2015;20:78-104.
Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, Sun W, et al. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol 2015;8(2):1466-78.
DOI: https://doi.org/10.21164/pomjlifesci.173
Copyright (c) 2016 Sylwia Szeląg, Mateusz Kurzawski
License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/